APA

Portillo J., Martin B., Hernandez R., Correas M., Gutierrez J., Del Valle J., Roca A., Vega A., Villanueva A. & Gutierrez R. (19970314). Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. : Urology.

Chicago

Portillo J, Martin B, Hernandez R, Correas M, Gutierrez J, Del Valle J, Roca A, Vega A, Villanueva A and Gutierrez R. 19970314. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. : Urology.

Harvard

Portillo J., Martin B., Hernandez R., Correas M., Gutierrez J., Del Valle J., Roca A., Vega A., Villanueva A. and Gutierrez R. (19970314). Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. : Urology.

MLA

Portillo J, Martin B, Hernandez R, Correas M, Gutierrez J, Del Valle J, Roca A, Vega A, Villanueva A and Gutierrez R. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. : Urology. 19970314.